Search
Clinician Ordering Portal
Scientific evidence
Guidance of sentinel lymph node biopsy decisions in patients with T1–T2 melanoma using gene expression profiling
Jan 2019
Multicenter prospective study in T1-T2 tumors showed combining GEP with Breslow thickness and age can provide a more precise determination of SLN positivity risk.
Publication: Future Oncology
Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria
Jan 2019
Discovery of reduced RFS for patients with thin tumors and Class 2B biology and cumulative validation cohort for DecisionDx-Melanoma. DecisionDx-Melanoma was the strongest independent predictor of RFS, DMFS and MSS.
Publication: Journal of the American Academy of Dermatology
Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test
Dec 2018
Independent study of the predictive accuracy of the GEP test, to determine what clinical and histopathologic features predict high-risk classification, and to evaluate how intermediate classes (1B & 2A) performed clinically. Patients with GEP Class 2 result were 22 times more likely to metastasize compared to a Class 1 result.
Publication: Dermatologic Surgery
Management decisions made by physician assistants and nurse practitioners in cutaneous malignant melanoma patients: impact of a 31-gene expression profile test
Nov 2018
Survey to determine the impact of 31-GEP test results on management decisions made by dermatology PA/NPs for cutaneous melanoma patients.
Publication: Journal of Drugs and Dermatology
Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder
Aug 2018
Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma
Aug 2018
To compare the prognostic accuracy of gene expression profiling (GEP) combined with PRAME status versus the clinical Tumor-Node-Metastasis (TNM) staging in patients with uveal melanoma (UM).
Publication: Am J Ophthalmol
Do largest basal tumor diameter and the American Joint Committee on Cancer's cancer staging influence prognostication by gene expression profiling in choroidal melanoma
Aug 2018
Purpose: to evaluate the prognostication of choroidal melanoma (CM) by the gene expression profiling (GEP) test.
Publication: American Journal of Ophthalmology
Clinical experience with a multiplexed immunofluorescence tissue biomarker assay (Tissue Cypher BE) in the management of Barrett’s esophagus: a single center experience
Jun 2018
Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.
Publication: Poster presentation (Su1109) at DDW 2018, Washington DC
Factors affecting dermatologists' use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma
May 2018
Survey and clinical vingettes to determine the impact of three factors - Breslow thickness, ulceration, and sentinel lymph node biopsy status - on the decision to order the 31-GEP test.
Publication: Journal of Drugs and Dermatology
Prospective multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients
Mar 2018
Initital data from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits.
Publication: SKIN: Journal of Cutaneous Melanoma
Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients
Feb 2018
Study was designed to assess the analytical validity of the 31-GEP test.
Publication: Diagnostic Pathology